It is not surprising that the discovery of L-DOPA (levodopa, L-3,4, dihydroxyphenylalanine) as an effective agent against the symptoms of par kinsonism has evoked such interest. Although the full range of its side effects and toxic reactions will become known only after wider use, there is no longer any serious doubt as to its efficacy when carefully and properly used. Many patients who have been severely incapacitated in spite of surgical pro cedures and extensive medication have been able to return to meaningful mobility, occupation and activities of living. It is not, however, the final answer or the cure. Some patients may be helped little, if at all, and others cannot tolerate the drug because of adverse reactions. Even in those patients who are markedly or significantly helped, dosage regulation is a con tinued long term problem requiring a close partnership with a skilled and knowledgeable physician.
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In this paper, some of the background and rationale of this new therapy will be reviewed briefly and the results obtained thus far in the United States will be summarized from the reported series and from the patients treated at the University of Florida under the supervision of one of us (M. G.).
In the central nervous system many substances are found which are assumed to have roles in transmission or regulation of the nerve impulse. For the most, the precise action of each of these is unknown. The best known among these is acetylcholine which some consider to be uniquely involved with transmission at excitatory synapses. Others include gamma amino butyric acid, histamine, serotonin, norepinephrine and dopamine. Con centration of these substances varies in different parts of the nervous system. Thus, norepinephrine is present in high concentration in those anatomic structures related to autonomic function. The concentration of this cate cholamine in the hypothalamus is at least ten times that found in the ce rebral cortex 15 . Another major catecholamine fraction is dopamine which is found in high concentration in the corpus striatum. Concentration in the caudate nucleus is more than 50 times that of the cerebral cortex 15 . Although its precise role as a neurotransmitter is unknown, it is logical to hypothesize an important role in neuronal control of extrapyramidal motor activity. Early clinical trials of treatment with dopamine or its precursors were largely disappointing and gave few indications of the beneficial effects later noted 9 . 13 . Dopamine itself does not cross the blood-brain barrier but its precursor, DOPA (3,4, dihydroxyphenylalanine) does. Cotzias and co-workers Only 15 improved less than 25% and there were but three who worsened. For sco ring a weighted scale was used which included signs, symptoms and functional acti vities.
Methods of administration -Our schedule has called for an initial dose of levodopa of 250 mg. four times a day, increasing in increments of 500 mg. every two or three days to a maximum of eight grams daily. In many, early side effects limit this to smaller amounts and smaller increments spread over a longer period of time. Symptoms such as nausea and vomiting, agitation, insomnia or confusion are frequently limiting in terms of initial dosages and of rapidity of increase. In such patients one may obviate or minimize the difficulty by decreasing initial doses as low as 50 to 100 mg. three times a day and similarly reduce increments of increase. Cotzias and co-workers 4 , 5 start with much lower doses, increase more gradually. It is, perhaps, for this reason that they appear to have less difficulty with dose-limiting side effects than have others and have been able to treat success fully some patients who had unsuccessfully used the drug before.
The total dose required or tolerated varies from patient to patient and cannot be predicted with certainty. Furthermore dosage is subject to reduction or change with the passage of time because of induced transitory dyskinesias or other side effects. A reduction in dose requirement for sustained improvement has also been noted. Thus, a patient may reach a total dosage of six grams a day for maximum relief within tolerance. After several months because of limiting side-effects such as dyskinesia this might be reduced to three to four grams a day with continued relief to extent greater than that noted previously on the same amount of drug. In the University of Florida series there has been a disappointing regression in approximately half of the patients who were over 70 years of age or who had very severe disability. Increasing or reducing dosage has not been associated with signi ficant change in these patients.
Levodopa may be associated with improvement of all of the manifestations of parkinsonism. Initial effects appear to be principally a lessening of rigidity and amelioration of bradykinesia. Patients and famlies report an increased mobility, clearer speech and a quickening of mental processes. Depressive symptoms may be markedly reduced. Treatment has appeared to be more effective against bradyki nesia and rigidity than against tremor, per se.
Side effects -Side-effects may be dose limiting and thus interfere with effec tive therapy. Using smaller initial doses and smaller increments of increase may reduce the severity of those which limit treatment. Among the side effects fre quently observed are nausea or vomiting, anorexia, mental changes including con fusion and agitation, postural hypotension, episodic hypertension, flushing, dyskinesia and cardiac arrhythmias. Cotzias and colleagues 16 It should further be observed that the use of dopa in therapy was not a chance discovery but resulted ultimately from intelligent application of basic scientific research on the nervous system. Continuation of basic scientific investigation of nervous system function may lead to further information which can be translated ultimately into practical clinical terms.
SUMMARY
This paper has presented a brief review of the treatment of parkinsonism with levodopa. Although there are problems in the utilization of this amino acid in practical therapy, significant amelioration of the symptoms and signs of parkinsonism can be obtained and sustained over long periods of time. It is as yet too early to detect any potential of alteration in the basic progressive course of the disease.
